Health News

What is DehydraTECH and how is it revolutionizing drug delivery for many industries

 
 
Chris Bunka, the CEO of Lexaria Bioscience, a Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels and guest Chris Bunka discuss the following:
Please tell us a little bit about yourself, how Lexaria Bioscience started and the development of the company’s technology?
What exactly are DehydraTECH and its benefits?
Can you talk about your recent announcement with British American Tobacco?
What are fat-soluble active molecules and how can your technology lower overall dosing with pharmaceutical ingredients?
What type of drugs and areas can DehydraTECH increase bio-absorption?
Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.
DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.
Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
 
 
Website: lexariabioscience.com
Social Media Links: Facebook: facebook.com/lexariabioscience Linkedin: linkedin.com/company/lexaria-bioscience Twitter: twitter.com/LexariaBioCorp

The Future of Medical Recalls

 
 
Joan Melendez, the Founder and President at health-tech startup Xcelrate UDI joins eHealth Radio and the Health News and Technology Channels. Their technology, a medical device barcode scanning solution, identifies and prevents the use of recalled and faulty medical products and devices to improve patient safety at the point of care.
Listen to interview with host Eric Michaels and guest Joan Melendez discuss the following:
What is a Unique Device Identifier, and why has it become so relevant in recent times?
What kind of impact are medical recalls currently having on the healthcare industry and patients?
How could full-scale adoption of your barcode scanning technology change healthcare - for patients and the industry as a whole?
How can technology be better used across healthcare -- for communication, organisation, data storage?
The Closed Loop Automation Solution you’ve partnered on has introduced an electronic patient implant card. How will this benefit patients?
Tip: If you’ve had a medical device implanted or are about to, ask your doctor about how they are ensuring your implants are safe for use and how you will be notified of quality issues should your implants be recalled after they are implanted.
Founder and President Joan Melendez leads the team at Xcelrate UDI. Having been in the healthcare industry since her teens, Joan has become a passionate advocate for the safety of patients and for innovation in healthcare.
Xcelrate UDI is a healthcare technology and consulting services company that leverages the power of UDI (unique device identifier) barcode scanning technology to bridge the information gaps between data sources (provided by manufacturers and the FDA) for medical devices and physical supplies. Their vision? To be the industry’s most trusted partner in advancing UDI adoption to improve compliance with medical devices and reduce patient risk at the point of care.
 
 
Website: www.xcelrateudi.com
Social Media Links: Facebook: facebook.com/xcelrateudi  Linkedin: linkedin.com/company/xcelrate-udi  Instagram: instagram.com/xcelrateudi

Research shows that honey can be effective with respiratory illness

 
 
Dr. Baljit Khamba, a clinic supervisor at Bastyr University Clinic and a core faculty member at Bastyr University California joins eHealth Radio and the Health News Channel.
Bastyr University is a nonprofit, private university offering doctoral, graduate and undergraduate degrees, with a multidisciplinary curriculum in science-based natural medicine. Recognized globally for its rigorous curriculum and strong research, the 42-year-old University has campuses in Kenmore, Washington, and San Diego, California. Bastyr's international faculty educate future leaders in the natural health arts and sciences, with an emphasis on integrating mind, body, spirit and nature.
Listen to interview with host Eric Michaels and guest Dr. Baljit Khamba discuss the following:
Tell us how you and your colleagues came to this research idea.
What evidence did the research show that honey can be effective with respiratory illness?
Why is your immunity and respiratory health important right now?
How can you incorporate honey into your daily routine to support your immune system?
What are other ways people can boost their immune system?
Dr. Baljit Khamba is a clinic supervisor at Bastyr University Clinic and a core faculty member at Bastyr University California. She treats a variety of conditions but has special interest in nutritional approaches to anxiety, stress, depression, focus and attention, memory and cognition. She focuses on providing high quality care addressing the causes of disease and utilizes safe and effective natural treatments. She accepts patients and their families who are motivated to improve their health. Her emphasis is on disease prevention and health promotion through education and empowering her patients to become active participant in the management of their own health.
While completing bachelor and master’s degrees, she worked as a research analyst at the Centre for Addiction and Mental Health (CAMH), where she researched alcohol addiction and anxiety, as well as nutrition and mental health. Dr. Khamba also has experience working in integrative psychiatric clinics, as well as more generalized practice, as well as being involved with research projects at the University of Alberta on natural health product safety in psychiatric patients. Dr. Khamba also maintains a private telemedicine practice.
Websites: https://bastyr.edu | https://bastyrclinic.org

A Holistic Approach to Helping Depression, Anxiety, and Memory Loss

 
 
Dr. Bob DeMaria, the Founder of The Drugless Doctors, a chiropractic practice in Cleveland, OH and Naples, FL that also provides personalized nutrition, drugless lab testing, and breast thermography joins eHealth Radio and the Chiropractor and Mental Health Channels.
Listen to interview with host Eric Michaels and guest Dr. Bob DeMaria discuss the following:
What is mental health?
Why is there such an emphasis on mental health today?
How can the food we consume affect our mental health?
How can someone improve mental health conditions like depression and anxiety naturally?
If someone wanted to begin a roadmap to improve their mental health today, what are the first three things they can do?
Dr. Bob DeMaria is an accomplished healthcare provider with over forty years experience helping individuals from all over the world without ever prescribing a single medication. His educational background includes a degree in Human Biology, specialties in Spinal Engineering and Natural Orthopedic Treatments, valedictorian of his chiropractic class at National University of Health Sciences, and an NHD degree.
He is the founder of The Drugless Doctors, a chiropractic and nutrition-based practice, with locations in Cleveland, Ohio and Naples, Florida. His extensive research and clinical observations have been the foundation for his eleven books, including the new, “Dr. Bob’s Drugless Guide to Mental Health,” which he co-wrote with his wife, Debbie.
An avid fan of life after 5pm, Dr. Bob enjoys riding his bicycle, playing bocce, and celebrating any occasion with his family.
 
 
Website: druglessdoctor.com
Social Media Links: Instagram: instagram.com/druglessdoctor Facebook: facebook.com/druglessdoctor Twitter: twitter.com/druglessdoctor

JanOne, treating the opioid industry and bringing to market drugs with non-addictive pain-relieving properties

 
 
Tony Giordano, PhD and Chief Scientific Officer of JanOne (NASDAQ: JAN), which is focused on developing treatments for diseases that cause severe pain joins eHealth Radio and and the Health News and Pain Management Channels.
Listen to interview with host Eric Michaels and guest Tony Giordano, PhD discuss the following:
Can you tell me a bit about yourself and how you got interested in reducing the need for opioid prescriptions that led to your involvement with JanOne?
Please give us an overview of JAN101 and its recent developments.
It is estimated that 40% of opioid overdose deaths involve prescription opioids, how is JanOne tackling the issue?
What is Jan’s main focus when treating diseases that cause pain to millions around the world?
Could you please give us some insight on Jan’s treatment for PAD and how PAD can affect patients?
JanOne (NASDAQ: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease-associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives
 
 
Website: https://janone.com
Social Media Links: Facebook: facebook.com/JanOneOfficial  Linkedin: linkedin.com/company/janone  Twitter: twitter.com/JanOne

Genprex, reprogramming the course of cancer and diabetes

 
 
Rodney Varner, the CEO of Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes joins eHealth Radio and the Cancer Information Diabetes and Health News Channels.
Listen to interview with host Eric Michaels and guest Rodney Varner discuss the following:
What inspires you at Genprex?
Please give us an overview of Genprex’s gene therapies in development. What is it intended to treat, and how does it work?
Could you talk more specifically about Genprex’s lead product candidate GPX-001?
Could you please give us some insight about GPX-002, gene therapy for people with diabetes and what is it comprised of?
What are the benefits of Genprex’s targeted therapies for people with non-small cell lung cancer?
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
 
 
Website: genprex.com
Social Media Links: Facebook: facebook.com/genprexinc  Linkedin: linkedin.com/company/genprex  Twitter: twitter.com/genprex

Citius Pharmaceuticals, dedicated to the development and commercialization of critical care products

 
Myron Holubiak, President and CEO of Citius Pharmaceuticals, and Leonard Mazur, Chairman of the Board at Citius Pharmaceuticals, a specialty late-stage pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives and cancer care joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guests Myron Holubiak & Leonard Mazur discuss the following:
Please give us an overview of catheter-related bloodstream infections (CRBSIs) and central venous catheters (CVCs).
Who is at Risk for Catheter-Related Bloodstream Infections (CRBSIs)?
Please give us a brief description of Minolok and how does it help the standard of care in the management of CRBSIs?
Give us a brief description of our NoveCite subsidiary and the impact of Covid 19 patients w ARDS. What is your technology and why is it different?
How is the development of MinoWrap for mastectomies progressing after your collaboration w MD Andersen?
Why did the both of you invest 26.5 million into the company?
Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC (“Triax”), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder, and, from 1995 to 2005, Chief Executive Officer, of Genesis Pharmaceuticals, Inc. (“Genesis”), a dermatological products company that marketed its products through dermatologists’ offices, and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company.
Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation, as Executive Vice President, ICN Pharmaceuticals, Inc., as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.
Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and has served in the US Marine Corps Reserves.
Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001.
Prior to that, he held sales and marketing positions at Roche during his 19-year tenure there. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also a director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016.
Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. (“Assembly”) and its predecessor, Ventrus Biosciences, Inc. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.
 
 
Website: citiuspharma.com

How the COVID-19 Pandemic is Worsening the Opioid Crisis

 
 
Dr. Joseph DeSanto, an Addiction Specialist with BioCorRx Inc., an addiction treatment solutions company targeting substance use and other related disorders joins eHealth Radio and the Addiction Prevention and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Joseph DeSanto discuss the following:
How has COVID-19 exasperated the US opioid crisis?
What added factors may cause addicts to relapse during the pandemic?
How has telehealth helped serve the addiction recovery community? Can you tell me how BioCorRx uses telehealth?
What makes the Beat Addiction Recovery Program unique?
With the winter holidays approaching, why are addicts more likely to relapse?
How can family members help loved ones get help and navigate their addiction during these unprecedented times?
Dr. Joseph DeSanto is a Board Certified Addictionologist for DeSanto Clinics and addiction specialist with addiction treatment solutions company, BioCorRx. He has more than 12 years of experience practicing medicine, is a graduate of Lafayette College and attended the State University of New York at Downstate in Brooklyn for his medical school training. He completed his internship and residency training at Cedars Sinai Medical Center in Los Angeles and is Board Certified by the American Board of Internal Medicine. In addition to his role with BioCorRx, he serves as a medical consultant for a number of treatment centers in Orange County, CA.
 
Website: BeatAddiction.com
Social Media Links: Twitter: twitter.com/biocorrxinc  Facebook: facebook.com/BioCorRx

CEO of Ready, Set, Food! Talks About Allergy Prevention For Babies!

 
 
Daniel Zakowski, the CEO and co-founder at Ready, Set, Food! - an innovative company that is working to help prevent babies from developing severe food allergies joins eHealth Radio and the Allergy Information & Health News Channels. Daniel even was on the hit show Shark Tank, where he got investor Mark Cuban to join the RSF team!
Listen to interview with host Eric Michaels and guest Daniel Zakowski discuss the following:
How did you come up with the Ready, Set, Food! product and concept?
What are the health benefits to kids taking it daily?
What is the recommended daily dosage?
For parents that may be worried about adding this to their infants bottles, what have the results been like?
Your product is partnering with hospitals and organizations around the US. Tell us more about what's to come!
 
 
Ready, Set, Food! is the first to introduce a system that is safe and easy for parents to gently introduce products to babies via powder packets that get added to a baby's bottle or food. The company has already helped reduce the risk of food allergies in kids by 80% and helped prevent over 200,000 babies across the US from developing those severe food allergies.
 
 
Website: readysetfood.com
Social Media Links: Instagram: instagram.com/readysetfood  Facebook: facebook.com/readysetfood

COVID-19 and Mental Health Issues: The Changing Picture

 
 
Dr. Jason Levine, Clinical Psychologist in private practice in Los Angeles that specializes in Substance Use Disorders, Anxiety, Depression, LGBTQ+ issues, and anger management joins eHealth Radio and the Mental Health & Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Jason Levine discuss the following:
How has the pandemic impacted people with previous mental health or substance abuse challenges?
What are some things people can do to lessen their anxiety or depression?
What is the CBT Model of treatment?
What do you see as challenges ahead as the pandemic numbers increase and there is uncertainty around when things will get better?
How can loved ones get involved if they see issues developing with someone in their family?
 
 
Dr. Levine is a licensed Clinical Psychologist born, raised, and clinically trained in New York. He has held a number of leadership positions throughout the years and is currently in private practice in Los Angeles, CA. His most recent position was as Senior Executive Director of Promises Treatment Centers in Malibu.
Dr. Levine offers expert treatment for those who seek a caring and highly experienced treatment provider. He offers highly individualized cognitive behavioral and psychodynamic treatment in his specialty areas of substance use, anxiety and depression, LGBTQ+, persons with HIV/AIDS, anger management and smoking cessation treatment. Dr. Levine has been trained at the Mayo Clinic in their Tobacco Specialist Training Program to provide expert vaping, chew and smoking cessation services.
Dr. Levine received his doctorate from the New School for Social Research in New York City and has since been providing clinical treatment and administrative oversight to a myriad of cutting-edge programs for over 25 years. Dr. Levine has always made it his priority to implement the most innovative treatment solutions for the most challenging issues.
Dr. Levine can be reached at: levinephd@gmail.com.
 
 
Website: www.jasonlevinephd.com
Social Media Links: Instagram: instagram.com/levinephd  Facebook: facebook.com/jasonlevinepsychologist
The beliefs, views, ideas, thoughts and opinions expressed on any program are those of the persons appearing on the program and do not necessarily reflect the views and opinions of the eHealth Radio Network.